<DOC>
	<DOCNO>NCT01134666</DOCNO>
	<brief_summary>This open-label , non-randomized , prospective , multicentric , Phase IV study evaluate FOLFIRI/ FOLFOX plus cetuximab first-line therapy subject KRAS wild-type metastatic CRC .</brief_summary>
	<brief_title>An Observational Study Evaluate Safety Efficacy FOLFIRI / FOLFOX Plus Cetuximab First-line Therapy Patients With KRAS Wild-type Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Cetuximab , chimeric immunoglobulin G1 ( IgG1 ) monoclonal antibody , find potentiate effect chemotherapy radiotherapy experimental system . The finding clinical trial suggest favorable risk-benefit ratio combination irinotecan oxaliplatin , infusional 5-FU/FA biweekly cetuximab , support current study demonstrate therapeutic value biweekly cetuximab regimen combination partner regimens subject KRAS wild-type mCRC first-line setting . The purpose study generate post marketing surveillance ( PMS ) data cetuximab first-line mCRC , mandate Licensing Authorities . This open-label , non-randomized , prospective , multicentric Phase IV study evaluate FOLFIRI/ FOLFOX plus cetuximab first-line therapy subject KRAS wild-type metastatic CRC . The study plan enroll 100 subject KRAS wild type CRC 20 centre across India . Tumour status , physical laboratory examination perform baseline visit . Subjects administer FOLFIRI/ FOLFOX cetuximab accord clinical condition follow treatment visit . Regular safety assessment adverse event ( AEs ) document throughout end-of-study visit . The outcome AEs ongoing final tumour assessment visit follow end-of-study visit ( If possible , 6 week last administration study medication second-line anticancer treatment , early 30 day end study treatment ) . Skin toxicity present end-of-study visit follow outcome know . OBJECTIVES Primary Objective : - To evaluate safety tolerability Cetuximab combination standard chemotherapy FOLFOX FOLFIRI first-line therapy patient KRAS wild-type metastatic colorectal cancer . Secondary Objective : - To evaluate efficacy Cetuximab combination standard chemotherapy first-line therapy patient KRAS wild-type metastatic colorectal cancer .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Subjects histologically confirm , adenocarcinoma colon rectum ( mCRC ) Subjects KRAS wildtype status tumour tissue Chemotherapy na√Øve subject Subject sign write informed consent ( per institutional protocol ) As per summary product characteristic cetuximab</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Colorectal neoplasm</keyword>
	<keyword>Intestinal neoplasm</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>cetuximab</keyword>
	<keyword>Erbitux</keyword>
</DOC>